Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens of millions of renminbi in a pre-Series A+ financing round. The funding round was led by Beijing state-owned Capital Operation and Management Center, with additional investments from Junshi Bio, Alwin Capital, and the company’s founder.
Company Background and Clinical Progress
Founded in 2018, Immupeutics Medicine is making strides in the clinical study of T-cell therapy IPM001 for third-line advanced hepatocellular carcinoma (HCC). The company has successfully completed the enrollment of subjects for low and medium dosages in its clinical trials. Encouragingly, no drug-related adverse events have been observed, and the therapy has shown superior safety and tolerability compared to standard treatments.
Clinical Efficacy and IND Filing
Several subjects in the trial have demonstrated clinical efficacy that surpasses second-line standard treatments. This has prompted Immupeutics Medicine to make an Investigational New Drug (IND) filing to the Center for Drug Evaluation (CDE), indicating the company’s progress towards potential regulatory approval.
First-in-Class mRNA Cancer Vaccine
In addition to its T-cell therapy, Immupeutics Medicine is also developing a first-in-class mRNA cancer vaccine for the treatment of liver cancer. This innovative vaccine has entered exploratory clinical studies, further highlighting the company’s commitment to advancing novel immunotherapies for cancer treatment.- Flcube.com
